ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDifferentiated structure of ‘2510 potentially ...

Title : APG990, a monoclonal antibody targeting OX40L, demonstrates safety and an extended half-life in healthy subjects (P3237) Presenter : Carl Dambkowski, M.D., Chief Medical Officer, Apogee ...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

August 11, 2025 - Previous articles in this series have explored identification, preservation, collection, review and production of novel data sources, but I would be remiss if I left out the last, ...

JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients ...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...

Bar charts are ubiquitous in the life-science literature, yet a study suggests that they’re often used in ways that can misrepresent research findings. The preprint 1, which was first posted on ...

Dr. Modur’s presentation will detail that BPM31510 has been well-tolerated in all three PCQD patients treated so far with no serious adverse events or drug related adverse events reported during the ...

NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on ...